NDA 215309 · Incyte Corp
Opzelura
Ruxolitinib Phosphate · Topical
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Jun 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Sep 21, 2021
Approved uses
3
Original approval plus efficacy supplements
Registered trials
453
74 Phase 3, 109 recruiting
FAERS reports
15,313
10,796 serious, 2,698 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, AND THROMBOSIS SERIOUS INFECTIONS Patients treated with oral Janus kinase inhibitors for inflammatory conditions are at risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )] . Reported infections include: Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Invasive fungal infections, including cryptococcosis, and pneumocystosis. Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens. Avoid use of OPZELURA in patients with an active, serious infection, including localized infections. If a serious infection develops, interrupt OPZELURA until the infection is controlled. The risks and benefits of treatment with OPZELURA should be carefully...
What it is approved for
From the label in effect Jun 30, 2026.
OPZELURA is a Janus kinase (JAK) inhibitor indicated for: the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ( 1.1 ) the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. ( 1.2 ) Limitations of Use Use of OPZELURA in combination with therapeutic biologics, other JAK inhibitors or potent immunosuppressants such as azathioprine or cyclosporine is not recommended. ( 1.3 ) 1.1 Atopic Dermatitis OPZELURA is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. 1.2 Nonsegmental Vitiligo OPZELURA is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. 1.3 Limitations of Use Use of OPZELURA in combination with therapeutic biologics, other Janus kinase (JAK) inhibitors, or potent immunosuppressants such as azathioprine or cyclosporine is not recommended.
Mechanism: Ruxolitinib, a Janus kinase (JAK) inhibitor, inhibits JAK1 and JAK2 which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. JAK signaling involves recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors, activation and subsequent localization of STATs to the nucleus leading to modulation of gene expression. The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 18, 2025 Supplement 7 · Efficacy LetterLabel
- Jul 18, 2022 Supplement 1 · Efficacy · priority review LetterLabelReview
- Sep 21, 2021 Original approval · Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated · priority review NovelLetterReviewLabel
1 products under this application
- OPZELURA · RUXOLITINIB PHOSPHATE EQ 1.5% BASE · CREAM, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ruxolitinib" as an intervention, any sponsor and status, largest first.
- INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01493414 · 2,233 participants · Start Aug 16, 2011 · Primary completion Jan 26, 2017
Drug: INC424 · For: Myelofibrosis
Sites: Algiers, Algeria; CABA, Argentina; Paraná, Argentina · 273 sites in all
- Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALLPivotal-lookingRecruiting
Bambino Gesù Hospital and Research InstituteAcademic, hospital or other
NCT07297914 · 1,000 participants (planned) · Start Jan 7, 2026 · Primary completion Nov 30, 2032
Drug: Blinatumomab; Cyclophosphamide and 1 more · For: Acute Lymphoblastic Leukemia (ALL); Stem Cell Transplant; Graft -Versus-host-disease
Sites: Vienna, Austria; Prague, Czechia; Copenhagen, Denmark · 9 sites in all
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaPivotal-lookingActive, not recruiting
St. Jude Children's Research HospitalAcademic, hospital or other
NCT03117751 · 790 participants · Start Mar 29, 2017 · Primary completion Sep 30, 2026
Drug: Prednisone; Vincristine and 21 more · For: Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma
Sites: Palo Alto, California; San Diego, California; Peoria, Illinois · 8 sites in all
- Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic DermatitisPivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT03745638 · 631 participants · Start Dec 20, 2018 · Primary completion Dec 23, 2019
Drug: Ruxolitinib Cream; Vehicle Cream · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Phoenix, Arizona; Fountain Valley, California · 79 sites in all
- TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic DermatitisPivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT03745651 · 618 participants · Start Dec 20, 2018 · Primary completion Nov 18, 2019
Drug: Ruxolitinib cream; Vehicle cream · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Fremont, California; Huntington Beach, California · 66 sites in all
- Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to RuxolitinibPivotal-lookingRecruiting
Kartos Therapeutics, Inc.Industry
NCT06479135 · 600 participants (planned) · Start Jun 3, 2024 · Primary completion Dec 31, 2026
Drug: Navtemadlin; Navtemadlin placebo and 1 more · For: Myelofibrosis; Post-PV MF; Post-ET Myelofibrosis and 2 more
Sites: Birmingham, Alabama; Gilbert, Arizona; Phoenix, Arizona · 215 sites in all
- MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia VeraPivotal-lookingRecruiting
University of BirminghamAcademic, hospital or other
NCT04116502 · 586 participants (planned) · Start Oct 25, 2019 · Primary completion Oct 31, 2028
Drug: Ruxolitinib; Hydroxycarbamide and 1 more · For: Polycythemia Vera
Sites: Aberdeen, United Kingdom; Bath, United Kingdom; Belfast, United Kingdom · 55 sites in all
- Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)Pivotal-lookingActive, not recruiting
Incyte CorporationIncyte (INCY)
NCT06959225 · 580 participants · Start Jun 23, 2025 · Primary completion Oct 29, 2026
Drug: Ruxolitinib Cream; Vehicle Cream · For: Hidradenitis Suppurativa
Sites: Phoenix, Arizona; Scottsdale, Arizona; Tempe, Arizona · 101 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use2,316
- drug ineffective1,422
- product use in unapproved indication859
- death797
- anaemia742
- pyrexia618
- pneumonia589
- thrombocytopenia564
- platelet count decreased536
- pruritus517
- haemoglobin decreased511
- fatigue462
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 11 |
| 2013 | 14 |
| 2014 | 22 |
| 2015 | 53 |
| 2016 | 104 |
| 2017 | 209 |
| 2018 | 299 |
| 2019 | 336 |
| 2020 | 530 |
| 2021 | 1,110 |
| 2022 | 1,775 |
| 2023 | 3,230 |
| 2024 | 2,774 |
| 2025 | 2,725 |
| 2026 | 2,121 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Opzelura (Ruxolitinib Phosphate)
2024 spending
$106M
Beneficiaries
19,146
50,464 claims
Per beneficiary
$5,531
$32.96 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $946,803 |
| 2022 | $24,255,429 |
| 2023 | $75,729,871 |
| 2024 | $105,903,177 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Immune Checkpoint Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis.
Nielsen DL, Juhl CB, Nielsen OH, et al. · JAMA Oncol 2024 · Systematic Review, Meta-Analysis
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
Mesa RA, Kiladjian JJ, Catalano JV, et al. · J Clin Oncol 2017 · Clinical Trial, Phase III, Comparative Study
- Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
Rosmarin D, Passeron T, Pandya AG, et al. · N Engl J Med 2022 · Clinical Trial
- Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Chu DK, Chu AWL, Rayner DG, et al. · J Allergy Clin Immunol 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Topical anti-inflammatory treatments for eczema: network meta-analysis.
Lax SJ, Van Vogt E, Candy B, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Corticosteroid-resistant immune-related adverse events: a systematic review.
Daetwyler E, Wallrabenstein T, König D, et al. · J Immunother Cancer 2024 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Incyte
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.